ストックスクリーナーアプリを入手
15.11
6.73%
-1.09
前日終値:
$16.20
開ける：
$15.95
24時間の取引高:
383.41K
Relative Volume:
1.12
時価総額：
$388.18M
収益：
-
当期純損益:
$11.77M
株価収益率:
26.12
EPS:
0.5785
ネットキャッシュフロー:
$-19.23M
1週間 パフォーマンス:
-2.52%
1か月 パフォーマンス:
-9.84%
6か月 パフォーマンス:
-33.49%
1年 パフォーマンス:
+7.70%
1日の値動き範囲:
$14.70
$16.20
1週間の範囲:
$13.27
$17.89
52週間の値動き範囲:
$11.56
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
TRML を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
15.11 | 398.17M | 0 | 11.77M | -19.23M | 0.5785 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-06 | 開始されました | Wedbush | Outperform |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-12-15 | 開始されました | Jefferies | Buy |
| 2023-12-04 | 再開されました | H.C. Wainwright | Buy |
| 2023-11-17 | 開始されました | Truist | Buy |
| 2023-10-31 | 開始されました | Guggenheim | Buy |
| 2023-10-25 | 開始されました | Piper Sandler | Overweight |
| 2022-10-20 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
すべてを表示
Tourmaline Bio Inc (TRML) 最新ニュース
BMO maintains $35 target on Tourmaline Bio, sees overreaction - Investing.com Australia
Tourmaline Bio stock holds $63 target post-Ph2 data By Investing.com - Investing.com Nigeria
BMO maintains $35 target on Tourmaline Bio, sees overreaction By Investing.com - Investing.com Nigeria
Tourmaline shares waver as investors mull mid-stage pacibekitug data - The Pharma Letter
In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD - insights.citeline.com
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff - BioPharma Dive
Tourmaline Bio (TRML) Shares Drop After Trial Data Release - GuruFocus
Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential - TipRanks
Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets - Endpoints News
Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein - marketscreener.com
Transcript : Tourmaline Bio, Inc.Special Call - marketscreener.com
Tourmaline Bio Announces Positive Phase 2 Trial Results - TipRanks
Tourmaline Bio Reports Positive Topline Data From Phase 2 TRANQUILITY Study - Nasdaq
Tourmaline Bio stock slips after trial data (TRML:NASDAQ) - Seeking Alpha
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial - marketscreener.com
Tourmaline shares edge lower despite phase 2 trial results - Investing.com Australia
Tourmaline Bio Announces Positive Topline Results from the - GlobeNewswire
Tourmaline Bio to reveal Phase 2 trial results tomorrow By Investing.com - Investing.com South Africa
Tourmaline Bio to reveal Phase 2 trial results tomorrow - Investing.com Australia
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - The Manila Times
Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease - Nasdaq
Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care - Stock Titan
Tower Research Capital LLC TRC Increases Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Contrasting Fennec Pharmaceuticals (NASDAQ:FENC) and VectivBio (NASDAQ:VECT) - Defense World
Tourmaline Bio’s Pacibekitug: A Promising IL-6 Inhibitor for ASCVD with Strong Buy Rating - TipRanks
Raymond James Financial Inc. Takes Position in Commercial Vehicle Group, Inc. (NASDAQ:CVGI) - Defense World
Barclays PLC Increases Position in Chicago Atlantic Real Estate Finance, Inc. (NASDAQ:REFI) - Defense World
Barclays PLC Acquires 5,175 Shares of Tile Shop Holdings, Inc. (NASDAQ:TTSH) - Defense World
Barclays PLC Purchases Shares of 24,107 Grail, Inc. (NASDAQ:GRAL) - Defense World
Barclays PLC Acquires 42,792 Shares of MicroVision, Inc. (NASDAQ:MVIS) - Defense World
Tourmaline Bio (TRML) to Release Quarterly Earnings on Monday - Defense World
FY2025 EPS Estimates for Tourmaline Bio Decreased by Analyst - Defense World
Chardan Capital Raises Earnings Estimates for Tourmaline Bio - Defense World
FY2025 EPS Estimates for Tourmaline Bio Raised by Analyst - Defense World
Tourmaline Bio Q2 EPS Estimate Decreased by HC Wainwright - Defense World
Analysts Set Expectations for Tourmaline Bio Q2 Earnings - Defense World
HC Wainwright Predicts Tourmaline Bio Q2 Earnings - Defense World
Wells Fargo & Company MN Boosts Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio Reports Q1 2025 Financial Results - TipRanks
Tourmaline Bio’s (TRML) “Buy” Rating Reaffirmed at Chardan Capital - Defense World
Tourmaline Bio (NASDAQ:TRML) Receives “Buy” Rating from HC Wainwright - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Barclays PLC - Defense World
Invesco Ltd. Buys Shares of 15,602 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Invesco Ltd. Purchases 1,181 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
CVS Health (NYSE:CVS) Price Target Raised to $71.00 - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of “Buy” from Brokerages - Defense World
Tourmaline Bio, Inc. SEC 10-Q Report - TradingView
Tourmaline (TRML) Projects Financial Stability into Late 2027 | TRML Stock News - GuruFocus
Tourmaline (TRML) Anticipates Key Data from Phase 2 Trial of Pacibekitug | TRML Stock News - GuruFocus
Tourmaline Bio Inc (TRML) 財務データ
収益
当期純利益
現金流量
EPS
Tourmaline Bio Inc (TRML) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
1.52%
1.15%
大文字化:
|
ボリューム (24 時間):